0000000000441799

AUTHOR

M.c. Parodi

showing 2 related works from this author

A simplified clinical risk score predicts the need for early endoscopy in non-variceal upper gastrointestinal bleeding

2014

Abstract Background Pre-endoscopic triage of patients who require an early upper endoscopy can improve management of patients with non-variceal upper gastrointestinal bleeding. Aims To validate a new simplified clinical score (T-score) to assess the need of an early upper endoscopy in non variceal bleeding patients. Secondary outcomes were re-bleeding rate, 30-day bleeding-related mortality. Methods In this prospective, multicentre study patients with bleeding who underwent upper endoscopy were enrolled. The accuracy for high risk endoscopic stigmata of the T-score was compared with that of the Glasgow Blatchford risk score. Results Overall, 602 patients underwent early upper endoscopy, and…

MaleVariceal bleedingClinical scoremedicine.medical_treatmentSeverity of Illness IndexEndoscopy GastrointestinalHEMORRHAGERecurrenceRisk FactorsProspective StudiesAged 80 and overOUTCOMESFramingham Risk Scoremedicine.diagnostic_testIncidenceUpper endoscopyGastroenterologyMiddle AgedTIMESurvival RateItalyFemaleGastrointestinal HemorrhageClinical risk factormedicine.medical_specialtyRisk AssessmentDiagnosis DifferentialClinical score Endoscopy High endoscopic stigmata Upper gastrointestinal bleeding; GLASGOW-BLATCHFORD HEMORRHAGE TIME OUTCOMESmedicineHumansUpper gastrointestinal bleedingAgedHepatologybusiness.industryReproducibility of Resultsnon variceal upper gastrointestinal bleedingEndoscopymedicine.diseaseTriageGLASGOW-BLATCHFORDEndoscopySurgerySettore MED/18 - Chirurgia GeneraleEarly DiagnosisHigh endoscopic stigmataROC CurveTherapeutic endoscopyUpper gastrointestinal bleedingTriagebusinessFollow-Up StudiesDigestive and Liver Disease
researchProduct

The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy.

2019

BACKGROUND We report a prospective, nationwide cohort evaluating the safety and effectiveness of CT-P13. METHODS A structured database was used to record serious adverse events (SAEs), clinical remission/response, inflammatory biomarkers (CRP and calprotectin), and endoscopic findings. RESULTS Eight hundred ten patients with inflammatory bowel disease (IBD) (452 Crohn's disease [CD]) were enrolled. Four hundred fifty-nine patients were naive to anti-TNFα (group A), 196 had a previous exposure (group B), and the remaining 155 were switched to CT-P13 (group C). All patients were included in the safety evaluation with a mean follow-up of 345 ± 215 days and a total number of 6501 infusions. One…

0301 basic medicineAdultMalemedicine.medical_specialtyAdolescentSettore MED/12 - GASTROENTEROLOGIABiosimilar; Crohn's disease; CT-P13; Inflammatory bowel disease; Inflectra; Infliximab; Remsima; Ulcerative colitis; Adolescent; Adult; Antibodies Monoclonal; Female; Follow-Up Studies; Gastrointestinal Agents; Humans; Inflammatory Bowel Diseases; Infliximab; Italy; Male; Prognosis; Prospective Studies; Young AdultInflectraInflammatory bowel diseaseInflammatory bowel diseaseAntibodies03 medical and health sciencesYoung Adult0302 clinical medicineGastrointestinal AgentsInternal medicineMonoclonalmedicineImmunology and AllergyHumansProspective StudiesRemsimaProspective cohort studyCrohn's diseasebusiness.industryCrohn's disease; ulcerative colitis; inflammatory bowel disease; Infliximab; Remsima; Inflectra; biosimilar; CT-P13BiosimilarSettore MED/09 - MEDICINA INTERNAGastroenterologyAntibodies Monoclonalmedicine.diseaseInflammatory Bowel DiseasesPrognosisUlcerative colitisInfliximabInfliximabCrohn's disease030104 developmental biologyUlcerative colitisItalyCohort030211 gastroenterology & hepatologyFemaleCalprotectinbusinessCT-P13Cohort studymedicine.drugFollow-Up StudiesInflammatory bowel diseases
researchProduct